Guyer William

Guyer William, Chief Development Officer at Corcept Therapeutics (CORT), has demonstrated a clear selling bias in recent insider transactions, with no open-market purchases recorded in the past year. Since September 2025, Guyer has executed 12 sales totaling approximately $6.5 million, including multiple seven-figure dispositions. The largest single sale occurred on October 7, 2025, when he disposed of shares worth $1.8 million, followed by a $1.55 million transaction on December 2, 2025. These disposals were accompanied by smaller but consistent sales, such as $364,070 on November 25, 2025, and $296,346 on March 4, 2026. The pattern intensified in early 2026 with three separate sales in February and March, including an $817,334 transaction on February 3 and a $423,730 sale on March 20. Guyer's activity shows a concentrated focus on Corcept, with all 37 recorded transactions involving CORT shares. While he has acquired shares through awards and other non-open-market means—totaling $3.93 million in buy-side activity—his disposals have significantly outweighed acquisitions, with $11.8 million in total sales. The transactions frequently involve both market sales (code S) and dispositions to satisfy tax obligations (code M), the latter consistently at $433,000 per event. This sustained selling pattern, particularly the absence of any recent purchases, suggests ongoing portfolio rebalancing or liquidity needs tied exclusively to his position in Corcept Therapeutics.